Health · 11 views
STAT+: A standing ovation for RevMed, and caution for Akeso
ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy.
Source STAT AI Summary Updated May 31, 2026
Health 
Story intelligence Beta
Freshness Stale Updated May 31, 2026
Confidence Limited Single-outlet story
Coverage Single outlet
Views 11 Community interest
Read time 1 min ~22 words
AI Summary
ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy.
Read full article on StatnewsAI summaries can be wrong sometimes—always verify important details using the source article.
SUPPORT HAPPENINGNOW · Independent AI News Intelligence
Enjoyed this article? Consider supporting HappeningNow to help keep independent AI-powered news analysis moving forward. Your contribution helps cover infrastructure, AI summaries, and continued platform development.
Support HappeningNowMore from Health
Continue reading recent Health coverage